Impact of HIV-1 RNA Assay Selection on Low-Level Viremia and Clinical Trial Endpoint Interpretations

Clicks: 5
ID: 321194
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #222 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Accurate plasma HIV-1 viral load quantification is essential for monitoring responses to antiretroviral therapy (ART) and defining efficacy in clinical trials. Differences in assay performance characteristics may result in discordant results and affect clinical interpretation. We evaluated concordance between the Roche cobas 6800 and Abbott RealTime HIV-1 RNA assays in 2 ongoing, multicenter, phase 3b trials. Methods Stored paired plasma aliquots from adults with HIV-1 who were virologically suppressed or initiating ART (271 and 348 paired samples, respectively) were batch re-tested using the RealTime assay; sample selection included all specimens from pre-specified key study visits and was enriched for selected centrally reported cobas 6800 results ≥50 copies/mL. Concordance was evaluated at clinically relevant categorical thresholds (50 and 200 copies/mL). Results Overall, among samples with cobas 6800 HIV-1 RNA results ≥50 copies/mL, 92% (91/99) of samples from participants who were virologically suppressed and 68% (159/233) from participants initiating ART were <50 copies/mL by RealTime. Among samples with cobas 6800 HIV-1 RNA results ≥200 copies/mL, 78% (14/18) and 83% (44/53), respectively, were <200 copies/mL by RealTime. Most samples classified as <50 copies/mL by cobas 6800 were <50 copies/mL by RealTime. All samples classified as <200 copies/mL by cobas 6800 were <200 copies/mL by RealTime. In both studies, per-protocol case review identified no clinical contributors in most cases of viremia. Conclusions Marked discordance between assays was observed near clinically relevant low HIV-1 RNA thresholds. These findings highlight the importance of assay-specific interpretation of low-level viremia in trials and routine care, particularly near decision-making thresholds.
Reference Key
openalex_W7169189677 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anna María Geretti, Kehui Wang, Bliss Leverette, Kai Hove, Richard Grove, Jerry L Jeffrey, Miriam Jones, Riya Moodley, Sherene Min, Rebecca A Borsi, Kimberley Brown, Emílio Letang, Jean van Wyk, Parul Patel, Bryn Jones
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag435
URL
https://doi.org/10.1093/cid/ciag435
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.